

Optibrium Appoints Head of North American Operations to Support Growing Demand

Appointment marks the opening of new office in Cambridge, MA

CAMBRIDGE, UK, 2 September, 2015 – Optibrium, a developer of software for small molecule discovery and optimisation, today announced the appointment of Dr Tamsin Mansley in a new role as Head of North American Operations. The appointment marks the opening of Optibrium's new office in Cambridge, MA, USA and represents the next phase in the company's expansion plans and business growth, driven by the rapid adoption of its StarDrop™ software.

Tamsin will be responsible for Optibrium's operations in North America, supporting the company's existing client base and leading the development of new business opportunities for StarDrop and the company's full range of products for small molecule design, optimisation and data analysis. Tamsin has over 10 years of experience developing, supporting and selling computational modelling and chemoinformatics software. Tamsin's passion for supporting project teams, enabling them to gain the best value from their software, is complemented by her post-doctoral research at the University of Texas and experience as a medicinal chemist at Eli Lilly and UCB Research.

Tamsin commented, "I am excited to join Optibrium and looking forward to working with both existing and new clients, and supporting the Optibrium community across North America. I have a great respect for Optibrium's strong scientific focus and vision for the future development of its products."

Matthew Segall, CEO of Optibrium, commented, "Engaging with and supporting our users is Optibrium's top priority and this exciting development enables us to enhance our ability to provide local support in North America. Tamsin's appointment and the expansion of our team of scientists, celebrates the company's success."

Optibrium's StarDrop software suite helps researchers to deliver optimally balanced, successful compounds. It brings confidence and intuitive simplicity to decision making; guiding and validating the direction taken by project teams and which compounds are prioritised. StarDrop works by evaluating project teams' complex data, which is often uncertain because of experimental variability or predictive error. Its interactive tools then enable researchers to efficiently explore ways to further improve their chosen compounds.

For further information on Optibrium and StarDrop, please visit www.optibrium.com/stardrop/, contact info@optibrium.com or call +44 1223 815900.

ENDS

Notes to Editors:



For high resolution image please email sarah.jeffery@zymecommunications.com

Media contact

Sarah Jeffery

Zyme Communications

E-mail: sarah.jeffery@zymecommunications.com

Phone: +44 (0) 7771 730919

Optibrium

Nick Foster

Director, Business Development

E-mail: nick.foster@optibrium.com

Phone: +44 (0)1223 815900

About Optibrium Ltd.

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium's portfolio of products includes:

- StarDrop™, which brings confidence to the selection and design of high quality candidate compounds. StarDrop creates an intuitive, highly visual and flexible environment to facilitate and speed up lead identification and optimisation, quickly targeting effective candidate compounds with a high probability of success downstream.
- Sentira™, an easy-to-use, dynamic data visualisation platform that helps to quickly spot patterns in compound data, analyse structure-activity relationships and elegantly present and report results.
- Asteris™, an iPad app that enables researchers to explore new compound ideas when and where they want, by combining highly intuitive chemistry drawing tools with StarDrop's visually informative predictive modelling.

Founded in 2009, Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

Visit the online community at <http://www.optibrium.com/community/> for further discussions on improving the productivity of drug discovery.